A seat protection pad to protect a seat against spilled liquids and other bodily fluids including human and animal fluids, including a base pad having a first side and a second side and a front portion, a mid-section portion and a rear portion, wherein the base pad includes a base pad opening located between the mid-section portion and the front portion, an upper pad having a first side and a second side and a front end and a rear end, wherein the upper pad is attached to the first side of the base pad at a location adjacent to the front portion of the base pad such that the second side of the upper pad is located adjacent to the first side of the base pad, an upper pad opening located between the front end of the upper pad and the front portion of the base pad such that the upper pad opening is aligned with the base pad opening to allow a seat belt buckle to be inserted through the base pad opening and the upper pad opening, a plurality of adhesive strips located on the second side of the base pad, wherein a first one of the plurality of adhesive strips is attached adjacent to the rear portion of the base pad, a second one of the plurality of adhesive strips is attached adjacent to the mid-section portion of the base pad and a third one of the plurality of adhesive strips is attached adjacent to the front portion of the base pad, and a plurality of stitches located on each of the plurality of adhesive strips for securing the plurality of adhesive strips to the base pad.

Devices and methods relate to inducing or promoting hemostasis. The hemostasis device may include a support layer having a first surface and an opposing second surface. The device may include a layer, the layer disposed on the first surface. The layer may include a target surface configured to contact a target site. The layer may include a monolayer of about 100% graphene or may include laser-reduced graphene oxide. The device may include a sensor configured to measure a level of hemostasis of the target site. The methods relate to a method of manufacturing a hemostatic device including a monolayer of graphene or a layer of laser-reduced graphene oxide.

Cellulose cyanoacrylate is employed either to bond two surfaces or to duplicate the shape of a three-dimensional object. The method is carried out by applying a release material to the object to be duplicated, applying a sheet of cellulosic material formed of wood fibers onto the three dimensional object, then saturating the sheet of cellulosic material with a cyanoacrylate glue and permitting the saturated sheet to cure. The resulting product duplicates the shape of the object. Two surfaces may be bonded by placing a sheet of cellulosic material between the two surfaces and applying the cyanoacrylate glue to edges of the sheet until saturated and allowing it to cure. Paper toweling may favorably be employed as the cellulosic material. This material may also be employed in bone or tooth repair. A break or fracture in an article can be repaired by positioning a sheet of cellulosic material over the break, saturating it with cyanoacrylate glue, and holding the saturated sheet in place with a releasable film. Irritating fumes may be suppressed by covering the saturated cellulosic material with a release film.

An oral product includes a matrix including a mixture of a plurality of capsules, a powdered component, a viscous component and a binder and wherein the matrix is molded into a shape. In a preferred embodiment, the capsules provide functional and flavorful ingredients. In an embodiment, the matrix is enclosed in a porous material that forms a pouch.

A stable, controlled release formulation for oral dosing of vitamin D compounds is disclosed. The formulation is prepared by incorporating one or more vitamin D compounds into a solid or semi-solid mixture of waxy materials. Oral dosage forms can be prepared by melt-blending the components described herein and filling gelatin capsules with the formulation.

A stable, controlled release formulation for oral dosing of vitamin D compounds is disclosed. The formulation is prepared by incorporating one or more vitamin D compounds into a solid or semi-solid mixture of waxy materials. Oral dosage forms can be prepared by melt-blending the components described herein and filling gelatin capsules with the formulation.

An adhesive formulation is provided for use in a film wound dressing. The adhesive formulation includes a medical-grade adhesive and an antimicrobial substance. This adhesive formulation may be coated onto one or more surfaces of a medical-grade transparent film suitable for a wound dressing. The antimicrobial material may be a silane quaternary ammonium salt. The silane quaternary ammonium salt may comprise 3-(trimethoxysilyl) propyldimethyloctadecyl ammonium chloride. The 3-(trimethoxysilyl) propyldimethyloctadecyl ammonium chloride may constitute about 72% of the silane quaternary ammonium salt. The medical-grade adhesive may comprise an acrylic adhesive. Further, the adhesive formulation may include about 0.01% to about 60% of the antimicrobial substance. The transparent film dressing may further include a release liner applied over the coated side(s) of the transparent film. The transparent film may comprise polyurethane.

An adhesive formulation is provided for use in a film wound dressing. The adhesive formulation includes a medical-grade adhesive and an antimicrobial substance. This adhesive formulation may be coated onto one or more surfaces of a medical-grade transparent film suitable for a wound dressing. The antimicrobial material may be a silane quaternary ammonium salt. The silane quaternary ammonium salt may comprise 3-(trimethoxysilyl) propyldimethyloctadecyl ammonium chloride. The 3-(trimethoxysilyl) propyldimethyloctadecyl ammonium chloride may constitute about 72% of the silane quaternary ammonium salt. The medical-grade adhesive may comprise an acrylic adhesive. Further, the adhesive formulation may include about 0.01% to about 60% of the antimicrobial substance. The transparent film dressing may further include a release liner applied over the coated side(s) of the transparent film. The transparent film may comprise polyurethane.

Described are systems and methods for monitoring administration of nitric oxide (NO) to ex vivo fluids. Examples of such fluids include blood in extracorporeal membrane oxygenation (ECMO) circuits or perfusion fluids used for preserving ex vivo organs prior to transplanting in a recipient. The systems and methods described herein provide for administering nitric oxide to the fluid, monitoring nitric oxide or a nitric oxide marker in the fluid, and adjusting the nitric oxide administration.

Methods and apparatus for a biodegradable multi-layer device suitable for medical applications are provided, wherein the device is formed from multiple film-layers configured to have different characteristics from one another such as different release profiles for therapeutic agents, adhesive properties, stiffness properties, and solubility properties. The film-layers may include a solid fibrinogen component. A device having multiple film-layers may take a non-adherent form during delivery to a target location within or on tissue, and thereafter may be exposed to moisture to take an adherent form on the tissue. The device may include a number of additives, including materials to improve the mechanical properties of the device, or one or more therapeutic or contrast agents.